Does Fish Oil Reduce Inflammation? What 68 Trials and the VITAL Study Show

Written by the Nuvirox Research Team

Short answer: modestly, and not for everyone. Pooled data from dozens of randomized trials show that fish oil (EPA and DHA) lowers blood markers of inflammation like C-reactive protein (CRP) and interleukin-6 (IL-6) by small amounts. The effect is most consistent in people who start with some low-grade inflammation and are not obese. The biggest long-term trial in generally healthy older adults found no significant change. The fair reading is that fish oil nudges inflammation, but it does not turn it off.

How could fish oil affect inflammation at all?

EPA and DHA move into the membranes of immune cells and change which signaling molecules those cells make. That is the core mechanism, and it is well described. In a widely cited review, Philip Calder explains that EPA and DHA partly displace arachidonic acid, an omega-6 fat, from cell membranes. Arachidonic acid is the raw material for many pro-inflammatory prostaglandins and leukotrienes. When there is less of it, fewer of those messengers are made, and the ones made from EPA tend to be less potent.

Calder's review describes a few other effects as well:

• Resolution mediators. EPA and DHA are precursors to resolvins, protectins and maresins. These molecules help an inflammatory response wind down instead of lingering.
• Gene-level signaling. Omega-3s can damp activation of NF-κB, a switch that turns on inflammatory genes, and can activate PPAR-γ, which acts on the anti-inflammatory side.
• Cell traffic. They partly reduce how readily white blood cells stick to blood vessel walls and migrate into tissue.

None of this works like a drug switch. These are partial, dose-dependent shifts, so the effects on blood markers in human trials are modest. (For how this mechanism stacks up against another widely studied option, see how curcumin and fish oil compare for inflammation.)

What human studies actually show

The randomized trial evidence leans positive but is uneven. The strongest signals come from people with chronic conditions and from longer trials. The weakest come from people with obesity and from one very large trial in mostly healthy older adults.

Li 2014 meta-analysis (68 RCTs, 4,601 participants): This is the broadest pooled look at fish oil supplements and three core inflammatory markers. In people with chronic non-autoimmune conditions, supplementation lowered CRP by about 18% and IL-6 by about 20%, but the pooled TNF-α effect was not significant. In healthy participants, CRP fell about 16% and TNF-α about 11%. The IL-6 drop in healthy people was only marginal (about 9%, P = 0.065). Longer supplementation produced larger IL-6 and TNF-α effects, and the benefit weakened when body mass index was above 30. Eating fish, as opposed to taking supplements, was assessed only in people with chronic disease and lowered IL-6 but not CRP or TNF-α.

Kiecolt-Glaser 2012 RCT (n = 138, 4 months, 1.25 or 2.5 g/day omega-3s): Healthy, sedentary, overweight middle-aged adults were randomized to one of two fish oil doses or placebo. Serum IL-6 fell 10% and 12% in the two omega-3 groups and rose 36% in the placebo group. TNF-α was roughly flat with omega-3s and rose 12% with placebo. Much of the gap reflects markers climbing in the placebo group, a pattern worth noting when reading headlines about this study.

Amlashi 2025 dose-response meta-analysis (40 RCTs, cardiometabolic populations): In people with cardiovascular disease, metabolic syndrome or hypertension, CRP fell non-linearly with dose up to about 1,200 mg/day of combined EPA and DHA. In people who were overweight or obese, the pooled analysis showed no significant CRP reduction, and the dose-response analysis found no clear trend either.

VITAL inflammation sub-study, Dong 2022 (n = 1,054, 4 years, 1 g/day marine omega-3s): This is the most important null result. VITAL was a large, double-blind, placebo-controlled trial. Researchers measured hs-CRP, IL-6, IL-10 and TNF-α at baseline, year 2 and year 4 in participants averaging about 65 years old. After adjustment for multiple comparisons, marine omega-3s did not significantly change any of these markers at either time point. In older adults who were not selected for elevated inflammation, a standard 1 g/day dose did not measurably shift circulating markers over four years.

What users report

This section is anecdotal and comes from public reviews, not controlled data. Public reviews of a prescription omega-3 ethyl ester product (on RxList) show a recognizable pattern. A minority of reviewers mention less joint or back discomfort. More reviewers focus on triglyceride changes, sometimes noticed only after months. The single most common complaint was burping, gas, heartburn or a fishy aftertaste, followed by capsules smelling rancid. These reports cannot tell you how often any effect happens, and they come from a small, self-selected group. They do match what trials suggest, though: any noticeable change tends to be slow and subtle, and stomach tolerability decides whether people stick with it.

What fish oil won't do

Fish oil will not reliably lower inflammation markers in everyone, and it is not a substitute for finding out why inflammation is elevated. The VITAL null result and the weak effect in people with obesity are reminders that baseline status matters a lot.

• Heart rhythm. A meta-analysis of seven cardiovascular outcome trials (81,210 participants) found that marine omega-3 supplements were associated with a 25% higher relative risk of atrial fibrillation. The risk was greater in trials using more than 1 g/day (hazard ratio 1.49) than in trials using 1 g/day or less (hazard ratio 1.12).
• Bleeding. Across 11 randomized trials (120,643 patients), omega-3s overall were not linked to more bleeding (rate ratio 1.09, 95% CI 0.91 to 1.31). High-dose purified EPA showed about a 50% relative increase in bleeding, but the absolute increase was small (0.6%). If you take an anticoagulant or antiplatelet drug, talk with your clinician before adding fish oil.
• Diet context. Supplements do not offset an overall eating pattern. Diet-wide approaches have their own evidence; see what the DASH diet does to inflammation markers.

See a doctor if your CRP stays elevated on repeat testing, or if you have unexplained joint swelling, fever, weight loss, persistent fatigue or pain. These can have medical causes that need a proper workup, not a supplement.

How much did trials use, and how long did it take?

Trials that moved inflammatory markers generally used about 1 to 2.5 g/day of combined EPA and DHA for at least several months. The Kiecolt-Glaser trial used 1.25 or 2.5 g/day for four months. The Amlashi dose-response analysis found CRP benefits leveling off around 1,200 mg/day of EPA plus DHA in cardiometabolic groups. VITAL's 1 g/day showed no marker change over four years in older adults. In the Li meta-analysis, longer supplementation was linked to larger IL-6 and TNF-α effects.

Because higher doses carry a dose-related atrial fibrillation signal, more is not automatically better. If you want an objective measure of whether your intake is changing your tissue levels, the omega-3 index tracks EPA and DHA in red blood cell membranes over roughly three to four months.

Frequently asked questions

How long does fish oil take to reduce inflammation?

Trials that found changes in inflammatory markers mostly ran for several months, and the Li meta-analysis found larger IL-6 and TNF-α effects with longer supplementation. Membrane fatty acid levels themselves take weeks to months to shift. Expect a timeline in months, not days.

Does fish oil lower CRP?

On average, modestly. Pooled trials show CRP reductions of roughly 16 to 18% in healthy and chronically ill groups. However, people who were overweight or obese saw no significant drop in a 2025 dose-response analysis, and VITAL found no significant change at 1 g/day. Your starting CRP and body weight seem to matter.

Is eating fish as good as taking fish oil for inflammation?

The evidence is thinner. In the Li meta-analysis, dietary fish intake was studied only in people with or at high risk of cardiovascular disease, and it lowered IL-6 but not CRP or TNF-α. Fish also brings protein and other nutrients that a capsule doesn't, so the comparison isn't purely about inflammation.

Is fish oil safe if I'm on blood thinners?

Pooled trial data did not show more bleeding with omega-3s overall, but high-dose purified EPA raised bleeding risk somewhat. Anyone on anticoagulants or antiplatelet drugs should check with their clinician first, especially before using higher doses.

Are other fatty acid supplements better for inflammation?

Not necessarily. Conjugated linoleic acid (CLA) is often marketed alongside fish oil, but pooled trials found that it raised CRP. See whether CLA reduces inflammation for the details.

The bottom line

Fish oil has a credible mechanism and a meta-analysis of 68 trials showing small reductions in CRP, IL-6 and TNF-α. Those results come with honest caveats: weaker effects in people with obesity, a large four-year null result at 1 g/day, and a dose-related atrial fibrillation risk above 1 g/day. Think of it as one modest lever among several, alongside diet pattern, activity and sleep, and get persistent inflammation checked by a doctor.

References

1. Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105-1115. DOI: 10.1042/BST20160474. PMID: 28900017.
2. Li K, Huang T, Zheng J, et al. Effect of marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: a meta-analysis. PLoS One. 2014;9(2):e88103. DOI: 10.1371/journal.pone.0088103. PMID: 24505395. PMCID: PMC3914936.
3. Kiecolt-Glaser JK, Belury MA, Andridge R, et al. Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun. 2012;26(6):988-995. DOI: 10.1016/j.bbi.2012.05.011. PMID: 22640930. PMCID: PMC3398219.
4. Amlashi MA, Payahoo A, Maskouni SJ, et al. Dose-dependent effects of omega-3 polyunsaturated fatty acids on C-reactive protein concentrations in cardiometabolic disorders: a dose-response meta-analysis of randomized clinical trials. Inflammopharmacology. 2025;33(5):2325-2339. DOI: 10.1007/s10787-025-01744-8. PMID: 40263171.
5. Dong Y, Zhu H, Chen L, et al. Effects of vitamin D3 and marine omega-3 fatty acids supplementation on biomarkers of systemic inflammation: 4-year findings from the VITAL randomized trial. Nutrients. 2022;14(24):5307. DOI: 10.3390/nu14245307. PMID: 36558465. PMCID: PMC9782648.
6. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine omega-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021;144(25):1981-1990. DOI: 10.1161/CIRCULATIONAHA.121.055654. PMID: 34612056. PMCID: PMC9109217.
7. Javaid M, Kadhim K, Bawamia B, et al. Bleeding risk in patients receiving omega-3 polyunsaturated fatty acids: a systematic review and meta-analysis of randomized clinical trials. J Am Heart Assoc. 2024;13(10):e032390. DOI: 10.1161/JAHA.123.032390. PMID: 38742535. PMCID: PMC11179820.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.